 |
 |
|
Home |
Current Issue |
Past Issues |
Audio/Video |
CME |
Collections |
In the Clinic |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 January 2002 | Volume 136 Issue 2 | Pages 161-172
Background: The use of aspirin to prevent cardiovascular disease events in patients without a history of cardiovascular disease is controversial.
Purpose: To examine the benefits and harms of aspirin chemoprevention.
Data Sources: MEDLINE (1966 to May 2001).
Study Selection: 1] Randomized trials at least 1 year in duration that examined aspirin chemoprevention in patients without previously known cardiovascular disease and 2) systematic reviews, recent trials, and observational studies that examined rates of hemorrhagic strokes and gastrointestinal bleeding secondary to aspirin use.
Data Extraction: One reviewer read and extracted data from each included article and constructed evidence tables. A second reviewer checked the accuracy of the data extraction. Discrepancies were resolved by consensus.
Data Synthesis: Meta-analysis was performed, and the quantitative results of the review were then used to model the consequences of treating patients with different levels of baseline risk for coronary heart disease. Five trials examined the effect of aspirin on cardiovascular events in patients with no previous cardiovascular disease. For patients similar to those enrolled in the trials, aspirin reduces the risk for the combined end point of nonfatal myocardial infarction and fatal coronary heart disease (summary odds ratio, 0.72 [95% CI, 0.60 to 0.87]). Aspirin increased the risk for hemorrhagic strokes (summary odds ratio, 1.4 [CI, 0.9 to 2.0]) and major gastrointestinal bleeding (summary odds ratio, 1.7 [CI, 1.4 to 2.1]). All-cause mortality (summary odds ratio, 0.93 [CI, 0.84 to 1.02]) was not significantly affected.
Data Synthesis: For 1000 patients with a 5% risk for coronary heart disease events over 5 years, aspirin would prevent 6 to 20 myocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events. For patients with a risk of 1% over 5 years, aspirin would prevent 1 to 4 myocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events.
Conclusions: The net benefit of aspirin increases with increasing cardiovascular risk. In the decision to use aspirin chemoprevention, the patient's cardiovascular risk and relative utility for the different clinical outcomes prevented or caused by aspirin use must be considered.
Author and Article Information
From University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and Air Force Medical Operations Agency and University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Disclaimers: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality, the U.S. Department of Defense, or the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank Kathleen Lohr, PhD; Sonya Sutton, BSPH; and Sheila White of Research Triangle Institute and Carol Krasnov of the University of North Carolina at Chapel Hill.
Grant Support: This study was developed by the RTI-UNC Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (290-97-0011).
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (http://www.ahrq.gov/clinic/prevenix.htm) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).
Current Author Addresses: Dr. Hayden: Division of General Medicine, Department of Medicine, 11C Ambulatory Care, Veterans Administration Medical Center.
Dr. Pignone: University of North Carolina Division of General Internal Medicine, CB 7110, 5039 Old Clinic Building, University of North Carolina Hospitals, Chapel Hill, NC 27599-7110.
Dr. Phillips: AFMOA/SGZZ, Population Health Support Division, 2606 Doolittle Road, Building 804, Brooks Air Force Base, TX 78235-5249.
Dr. Mulrow: Department of Medicine, University of Texas Health Science Center at San Antonio, 7400 Merton Minter Boulevard (11C6), San Antonio, TX 78284. CLINICAL GUIDELINES
Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rees, J. Stevenson, and on behalf of the British Menopause Society Council Primary prevention of coronary heart disease in women Menopause Int, March 1, 2008; 14(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mancia and G. Grassi Editorial: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 5 - 12. [PDF]
|
|
|
|
 |
|
 D. B. Hogan Defying dementia Can Fam Physician, February 1, 2008; 54(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Graff, N. von Hentig, K. Kuczka, C. Angioni, P. Gute, S. Klauke, E. Babacan, and S. Harder Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo J. Antimicrob. Chemother., February 1, 2008; 61(2): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hunt, D. Choquette, B. N. Craig, C. De Angelis, F. Habal, G. Fulthorpe, J. I. Stewart, A. G.G. Turpie, and P. Davis Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician, July 1, 2007; 53(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J E Parry Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves Evid. Based Nurs., July 1, 2007; 10(3): 79 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Budoff, L. J. Shaw, S. T. Liu, S. R. Weinstein, T. P. Mosler, P. H. Tseng, F. R. Flores, T. Q. Callister, P. Raggi, and D. S. Berman Long-Term Prognosis Associated With Coronary Calcification: Observations From a Registry of 25,253 Patients J. Am. Coll. Cardiol., May 8, 2007; 49(18): 1860 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.S. Preventive Services Task Force* Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, March 6, 2007; 146(5): 361 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dube, A. Rostom, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association Circulation, January 2, 2007; 115(1): 114 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care, January 1, 2007; 30(1): 162 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Pearson The Prevention Of Cardiovascular Disease: Have We Really Made Progress? Health Aff., January 1, 2007; 26(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]
|
|
|
|
 |
|
 T Marshall, S Bryan, P Gill, S Greenfield, K Gutridge, and Birmingham Patient Preferences Group Predictors of patients' preferences for treatments to prevent heart disease Heart, November 1, 2006; 92(11): 1651 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. O'Kennedy, L. Crosbie, S. Whelan, V. Luther, G. Horgan, J. I Broom, D. J Webb, and A. K Duttaroy Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 170 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 B. M. Psaty and J. D. Potter Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med., August 31, 2006; 355(9): 950 - 952. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Becker, J. Segal, D. Vaidya, L. R. Yanek, J. E. Herrera-Galeano, P. F. Bray, T. F. Moy, L. C. Becker, and N. Faraday Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy JAMA, March 22, 2006; 295(12): 1420 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, March 7, 2006; 144(5): 326 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, E. W Steyerberg, and C. de Laet The polypill: at what price would it become cost effective? J. Epidemiol. Community Health, March 1, 2006; 60(3): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Nijhuis, T. Stijnen, A. Peeters, J. C.M. Witteman, A. Hofman, and M. G. M. Hunink Apparent and Internal Validity of a Monte Carlo-Markov Model for Cardiovascular Disease in a Cohort Follow-up Study. Med Decis Making, March 1, 2006; 26(2): 134 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein Primum non nocere: Antithombotics after intracerebral hemorrhage? Neurology, January 24, 2006; 66(2): 162 - 163. [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey COX-2 chronology Gut, November 1, 2005; 54(11): 1509 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Woolf, E. C.Y. Chan, R. Harris, S. L. Sheridan, C. H. Braddock III, R. M. Kaplan, A. Krist, A. M. O'Connor, and S. Tunis Promoting Informed Choice: Transforming Health Care To Dispense Knowledge for Decision Making Ann Intern Med, August 16, 2005; 143(4): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick and S. M. Weisman Risk of Hemorrhagic Stroke With Aspirin Use: An Update Stroke, August 1, 2005; 36(8): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Elwood, G. Morgan, G. Brown, and J. Pickering Aspirin for everyone older than 50?: FOR BMJ, June 18, 2005; 330(7505): 1440 - 1441. [Full Text] [PDF]
|
|
|
|
|
|
C. Mulrow and M. Pignone An Editorial Update: Should She Take Aspirin? Ann Intern Med, June 7, 2005; 142(11): 942 - 943. [Full Text] [PDF]
|
|
|
|
|
|
M. R Nelson, D. Liew, M. Bertram, and T. Vos Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >=70 BMJ, June 4, 2005; 330(7503): 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Corman, B. A Fedutes, and N. T Ansani Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin Ann. Pharmacother., June 1, 2005; 39(6): 1073 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Bates and W. C. Lau Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease Circulation, May 3, 2005; 111(17): e267 - e271. [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. R. Cook, I-M. Lee, D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens, and J. E. Buring A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N. Engl. J. Med., March 31, 2005; 352(13): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Alberts, J. D. Potter, M. E. Martinez, L. M. Hess, A. Stopeck, and P. Lance What Happened to the Coxibs on the Way to the Cardiologist? Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 555 - 556. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction Ann Intern Med, February 1, 2005; 142(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Morgan What next for low dose aspirin? J. Epidemiol. Community Health, January 1, 2005; 59(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, L. S Simon, and G S. Gazelle Analysis of Aspirin-Associated Risks in Healthy Individuals Ann. Pharmacother., January 1, 2005; 39(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36. [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Persell and D. W. Baker Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities Arch Intern Med, December 13, 2004; 164(22): 2492 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. I. Shireman, P. A. Howard, T. F. Kresowik, and E. F. Ellerbeck Combined Anticoagulant-Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients Stroke, October 1, 2004; 35(10): 2362 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Woloshin and L. M. Schwartz Association of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk JAMA, September 22, 2004; 292(12): 1426 - 1427. [Full Text] [PDF]
|
|
|
|
 |
|
 J. van Ryn, M. Kink-Eiband, I. Kuritsch, U. Feifel, G. Hanft, G. Wallenstein, G. Trummlitz, and M. Pairet Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers J. Clin. Pharmacol., July 1, 2004; 44(7): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pletcher, J. A. Tice, M. Pignone, and W. S. Browner Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis Arch Intern Med, June 28, 2004; 164(12): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Cox, M. Frisse, A. Behm, and K. A. Fairman Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users Arch Intern Med, June 14, 2004; 164(11): 1243 - 1246. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hur, N. S. Nishioka, and G. S. Gazelle Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus J Natl Cancer Inst, February 18, 2004; 96(4): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Sandler Aspirin Prevention of Colorectal Cancer: More or Less? Ann Intern Med, February 3, 2004; 140(3): 224 - 225. [Full Text] [PDF]
|
|
|
|
 |
Article
